Nexus Pharmaceuticals received U.S. Food and Drug Administration approval for the company’s New Drug Application for Emerphed, the first premixed ephedrine in a ready-to-use 50 mg/10 mL vial.
The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.
